TriSalus Life Sciences reports Q4 EPS (21c), consensus (14c)

Reports Q4 revenue $13.205M vs $8.261M last year. “During our fourth quarter and throughout 2025, we continued to deliver strong commercial performance, supported by the growing clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications,” said Mary Szela, President and CEO of TriSalus. “We are pleased to have exceeded our 2025 revenue guidance of 50%, delivering 53%, reflecting strong commercial execution and sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver.”